Drug Development

The agreement states that Orbit will implement its bead-based peptide display engine to discover peptide leads specific to targets related to specific tumors.

Advanced analytical tools generate more data in today’s labs than ever before.

Webinar Date/Time: Wed, Oct 11, 2023 11:00 AM EDT

Excipients should be treated equally when it comes to quality management, risk assessment, and testing.

Coprocessed excipients save time and cost while improving performance in a widening array of dosage forms.

Pharma's ability to continually reinvent itself will be critical in growing future business operations.

Extensive research on various gene editing techniques could inform the future of mRNA therapies.

Twist Bioscience is a synthetic biology and genomics company that has developed a DNA synthesis platform to industrialize the engineering of biology, which is a new method of this process by “writing” DNA on a silicon chip.

Webinar Date/Time: Thursday, September 21, 2023 at 11am ET | 10am CT | 8am PT | 4 pm BST

Webinar Date/Time: Wed, Sep 20, 2023 11:00 AM EDT

The formulation will be used to mitigate emerging infectious diseases and public health emergencies.

FDA has halted enrollment in clinical studies for Gilead Sciences’ magrolimab, a biologic treatment in development for acute myeloid leukemia.

With this agreement, Chiesi Global Rare Diseases will co-develop drug delivery systems with Aliada Therapeutics for large-molecule therapeutics that can cross the blood-brain barrier.

A major grant from the Bill & Melinda Gates Foundation will bolster efforts to fight the global HIV/AIDS epidemic.

HitGen has entered into a research service agreement with Nested Therapeutics for use of HitGen’s DNA-encoded library for drug discovery.

Webinar Date/Time: Thu, Sep 28, 2023 11:00 AM EDT

The biggest hurdle is developing palatable formulations that are efficacious and patient friendly.

An intelligent drug development paradigm can enable small pharma to implement an effective early drug development approach.

mRNA may be a modality whose chief advances are yet to come.

An intelligent drug development paradigm can enable small pharma to implement an effective early drug development approach.

In this episode, David Tisi and Reenal Gandhi provide expert insights into advances and innovations changing the drug dosage form landscape.

Teva Pharmaceuticals and Alvotech will expand their partnership for the development and commercialization of biosimilar candidates.

Janssen has received a positive opinion from the EMA for two novel bispecific antibodies, TALVEY (talquetamab) and TECVAYLI (teclistamab), which the company is developing to treat blood cancer.

Newly launched Crossbow Therapeutics will work to advance a novel class of antibody therapies for treating cancers.